Chemometec
ChemoMetec A/S is a Danish medical technology company specializing in the development, manufacturing, and global commercialization of automated cell counting and cell analysis equipment. The company designs specialized analytical instruments, including its signature NucleoCounter product line, alongside proprietary disposable sampling cassettes, reagents, and image analysis software. Its automated systems are extensively utilized in cell-based immunotherapy research, biopharmaceutical manufacturing quality control, veterinary science, and academic life science research facilities. Principal revenue is derived from the direct commercial sale of analytical instruments, recurring high-margin sales of single-use sampling cassettes, software subscription licenses, and comprehensive equipment maintenance service agreements. ChemoMetec maintains a dominant market position in automated cell counting technology utilized within advanced cell and gene therapy manufacturing workflows globally. Headquartered in Allerød, Denmark, the company operates international sales subsidiaries across North America and Europe, with its common shares publicly listed and traded on Nasdaq Copenhagen under the ticker CHEMM.
20 of the funds FundTelligence covers report a position in Chemometec.
- Legal name
- Chemometec AS
- Sector
- Health Care
- Country
- Denmark
- Funds holding it
- 20
Funds holding Chemometec
- First Veritas — FIRST · 5.3 % (largest positions only, October 2026)
- TIN Ny Teknik — Tin Fonder · 3.91 % (full portfolio disclosed, June 2026)
- Kavaljer Quality Focus — Kavaljer · 3.2 % (partially disclosed portfolio, October 2026)
- Handelsbanken Microcap Norden — Handelsbanken · 2.75 % (full portfolio disclosed, October 2026)
- D&G Småbolag — Carnegie · 2.0 % (full portfolio disclosed, June 2026)
- Carnegie Småbolagsfond — Carnegie · 1.57 % (full portfolio disclosed, June 2026)
- Schroder ISF Nordic Smaller Companies — Schroders · 1.48 % (full portfolio disclosed, June 2026)
- Handelsbanken Nordiske SMB — Handelsbanken · 1.15 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 20 funds holding it.